Skip to content
DataLookout
Menu

NCT05991336

Growth and Development-related Outcomes in Children With Transfusion-dependent Beta-thalassemia After Gene Therapy

StatusRecruiting
PhaseNot specified
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 2 versions: 2 with changes below. See every version on ClinicalTrials.gov ↗

  1. Notable Primary completion moved earlier from Dec 31, 2028 to Dec 31, 2027
    • Primary endpoint(s) modified
    • Eligibility criteria expanded, about 20 words
    • Study completion moved earlier from Dec 31, 2029 to Dec 31, 2028
  2. Study First Submitted
  • Notable: the plan changed

Endpoints

Primary

Growth in pediatric subjects will be assessed by height.
Timeframe: Up to 5 years.
Growth in pediatric subjects will be assessed by weight.
Timeframe: Up to 5 years.
Growth in pediatric subjects will be assessed by bone density.
Timeframe: Up to 5 years.
The pubertal status will be measured using by Tanner scale.
Timeframe: Up to 5 years.
Quality of life will be measured using by Pediatric Quality of Life Inventory (PedsQL) at baseline and the end of the study.
Timeframe: Up to 5 years.

Arms and interventions

Gene therapy group

TDT Children who have received gene therapy between 3\~14 years old.

Supportive therapy group

TDT Children who received lifelong treatment with blood transfusions and iron chelation. They were selected based on the age and sex of the gene therapy group.

Healthy children group

Healthy children were selected based on the age and sex of the gene therapy group.

Genetic: Gene therapy

Sites

1 site in 1 country

  • Regenerative Medicine CenterTianjin, Tianjin Municipality, China